U.S. Markets open in 8 hrs 28 mins

Trevena, Inc. (TRVN)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.82-0.14 (-4.73%)
At close: 4:00PM EDT
People also watch
TTPHAKBAQUREFLXNZFGN

Trevena, Inc.

1018 West 8th Avenue
Suite A
King of Prussia, PA 19406
United States
610-354-8840
http://www.trevenainc.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees72

Key Executives

NameTitlePayExercisedAge
Dr. Maxine Gowen Ph.D.Chief Exec. Officer, Pres and Exec. Director784.52kN/A59
Dr. Michael W. Lark Ph.D.Chief Scientific Officer and Sr. VP of Research494.63kN/A60
Mr. John M. Limongelli Esq.Chief Admin. Officer, Sr. VP, Gen. Counsel and Corp. Sec.457.48kN/A47
Dr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardN/AN/AN/A
Dr. Jonathan Violin Ph.D.Scientific Co-Founder and Sr. Director of Investor RelationsN/AN/A42
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Trevena, Inc., a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include oliceridine injection, a µ-receptor G protein pathway selective modulator, which is in Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in preclinical development for the treatment of migraine; and TRV734, a small molecule G protein biased ligand at the mu-receptor that is in Phase I clinical trials for the treatment of moderate to severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. Trevena, Inc. was founded in 2007 and is headquartered in King of Prussia, Pennsylvania.

Corporate Governance

Trevena, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 8. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.